1. Home
  2. TRIN vs AKBA Comparison

TRIN vs AKBA Comparison

Compare TRIN & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TRIN
  • AKBA
  • Stock Information
  • Founded
  • TRIN 2007
  • AKBA 2007
  • Country
  • TRIN United States
  • AKBA United States
  • Employees
  • TRIN N/A
  • AKBA N/A
  • Industry
  • TRIN Finance/Investors Services
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • TRIN Finance
  • AKBA Health Care
  • Exchange
  • TRIN Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • TRIN 912.3M
  • AKBA 958.6M
  • IPO Year
  • TRIN 2021
  • AKBA 2014
  • Fundamental
  • Price
  • TRIN $14.16
  • AKBA $3.97
  • Analyst Decision
  • TRIN Hold
  • AKBA Strong Buy
  • Analyst Count
  • TRIN 3
  • AKBA 5
  • Target Price
  • TRIN $14.83
  • AKBA $6.90
  • AVG Volume (30 Days)
  • TRIN 837.6K
  • AKBA 5.0M
  • Earning Date
  • TRIN 08-06-2025
  • AKBA 08-07-2025
  • Dividend Yield
  • TRIN 14.38%
  • AKBA N/A
  • EPS Growth
  • TRIN 37.77
  • AKBA N/A
  • EPS
  • TRIN 2.19
  • AKBA N/A
  • Revenue
  • TRIN $240,010,000.00
  • AKBA $184,909,000.00
  • Revenue This Year
  • TRIN $24.11
  • AKBA $26.88
  • Revenue Next Year
  • TRIN $4.87
  • AKBA $44.34
  • P/E Ratio
  • TRIN $6.47
  • AKBA N/A
  • Revenue Growth
  • TRIN 30.65
  • AKBA N/A
  • 52 Week Low
  • TRIN $12.50
  • AKBA $0.93
  • 52 Week High
  • TRIN $16.82
  • AKBA $4.08
  • Technical
  • Relative Strength Index (RSI)
  • TRIN 44.05
  • AKBA 62.71
  • Support Level
  • TRIN $14.11
  • AKBA $3.48
  • Resistance Level
  • TRIN $14.32
  • AKBA $3.77
  • Average True Range (ATR)
  • TRIN 0.22
  • AKBA 0.17
  • MACD
  • TRIN -0.01
  • AKBA -0.04
  • Stochastic Oscillator
  • TRIN 48.72
  • AKBA 62.82

About TRIN Trinity Capital Inc.

Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: